Gotratix
A-18, muscle peptide bioregulator
Gotratix is a skeletal-muscle peptide complex, listed as A-18. It is the compound in this cohort where the class's own central claim — that these preparations restore an organ's protein synthesis — is most directly testable, because measuring muscle protein synthesis is a solved problem with a gold-standard method that has been in routine research use for decades. Nobody has pointed that method at this product, or at any product in this family.
Gotratix quick facts
| Reported research dose | 40-160mg daily (1-2 capsules, 1-2x daily with food · 40mg/capsule) |
| Route | Oral |
| Frequency | 1-2x Daily · Daily during a course |
| Half-life | Not characterized |
| Forms | Oral |
| Evidence level | Theoretical — Khavinson-school work, largely Russian-language and rarely replicated outside it |
The Khavinson literature behind this is decades deep, almost entirely Russian-language, and rarely replicated by any independent group — small single-arm series rather than controlled trials. Absence of replication is not evidence it fails; it is an absence of the evidence that would settle it either way. Dose and course length follow the manufacturer's convention, not a trial. Muscle-tissue directed, and the one people expect the most from and should expect the least from — no bioregulator is going to compete with training and protein. Course pattern: roughly 10 days on, then off, once or twice a year. To know whether it did anything, your actual lifting numbers, tracked the same way. Run it as an experiment you measure, not a protocol you trust.
What Gotratix actually is — and why that changes the mechanism
Gotratix is a skeletal-muscle peptide complex in capsules, listed as A-18. It is the page in this cohort where the class's own central claim can be pinned down hardest, because the claim is about protein synthesis and protein synthesis is a solved measurement problem.
The claim, and the method that already exists to test it. The class hypothesis is that an organ's short peptides restore that organ's protein synthesis toward a younger pattern. In skeletal muscle that quantity has a name and a gold-standard method: the fractional synthetic rate, measured by infusing a stable-isotope-labeled amino acid and taking muscle biopsies to see how fast the label appears in muscle protein. The technique has been in routine use in exercise and nutrition research for more than 30 years and it answers precisely the question this class asks. 0 studies have pointed it at this product or at any product in this family.
The tissue-specificity argument is at its weakest here, and the reason is scale. The whole premise is that an extract from one organ acts on that organ. Skeletal muscle is the largest tissue in the body by mass, spread across hundreds of separate muscles with different fiber compositions and different blood flows, and it is the only target in this cohort a reader can also load directly, 3 days a week, at no cost. 'Targets muscle' therefore narrows nothing at all — it is the least selective destination a preparation could name — and whatever a capsule contains is being diluted into the biggest compartment there is.
What the complex commits to, in numbers. A peptide of 2 residues has 400 possible identities, one of 3 residues has 8,000 and one of 4 residues has 160,000; the label selects none of them. The 2021 gene-expression review that carries this class's mechanism is indexed by sequence — 98 genes credited to AEDG, 36 to Lys-Glu — and holds 0 skeletal-muscle entries.
What the primary literature on Gotratix actually says
Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers
Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M · International Journal of Molecular Sciences 2022;23(14):7733 · PMID 35887081
The 2022 transport review. PEPT1 sits on the brush-border membrane of the small intestine and its substrate range is 'basically all di- and tripeptides' — molecules of 2 and 3 residues. This is the only named route by which an oral peptide reaches the circulation intact, and a complex of unstated chain length does not qualify for it.
Systematic search for structural motifs of peptide binding to double-stranded DNA
Kolchina N, Khavinson V, Linkova N, Yakimov A, Baitin D, Afanasyeva A, Petukhov M · Nucleic Acids Research 2019;47(20):10553–10563 · PMID 31598715
The 2019 docking screen, 108,800 peptide-DNA complexes, binder threshold near -32. Cited for scope: it screens defined sequences, and no muscle-derived peptide preparation appears in it because none has been characterized.
The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis
Alsulaimani RA, Quinn TJ (independent — not the Khavinson group) · Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709
The 2021 independent systematic review: 24 randomized trials, 2,245 participants, cognitive endpoints, risk of bias moderate to high, certainty of evidence low to very low. Included as calibration on what happens when someone outside this school grades it.
What is not here. Nothing is indexed under the trade name Gotratix. No strength, lean-mass or muscle protein synthesis endpoint has been published for a skeletal-muscle peptide preparation in this family. Searched through Europe PMC, PubMed and Google Scholar on 2 September 2026. Naming the gap is more useful than filling it with a paragraph of hedging.
Why the Gotratix evidence is weak — and what it still showed
Almost every human result in this class comes from one school — Vladimir Khavinson's institute in St Petersburg and the groups around it. That means single-center data, collected by the people who developed the compound, rarely blinded, never pre-registered, and reported across enough endpoints that something was always going to move. Read anything below against that.
Specific to Gotratix. The weakness specific to Gotratix is that its claim is unusually easy to test and unusually hard to hide behind. Muscle protein synthesis is measured directly by stable-isotope tracer infusion with muscle biopsies, reported as a fractional synthetic rate; the technique is standard, it has been used in hundreds of nutrition and exercise studies, and it answers exactly the question this class asks. Strength is measured by a dynamometer and lean mass by DEXA, both cheap by comparison. A muscle product with 0 published measurements of any of the three has not been held to a hard standard, it has not been held to any standard.
The count: 0. Nothing is indexed under the trade name Gotratix, and 0 strength, lean-mass or muscle protein synthesis endpoints have been published for a skeletal-muscle peptide preparation in this family. Searched through Europe PMC, PubMed and Google Scholar on 2 September 2026.
Why that zero is harder to excuse here than anywhere else in the cohort. This is the field with the cheapest endpoints in medicine. A handgrip dynamometer costs less than a course and is repeatable at 8-12 weeks. A DEXA scan for lean mass is routine. A 1-repetition-maximum test is free. And the gold-standard measurement of the exact quantity this class claims to change — fractional synthetic rate by stable-isotope tracer — has been available for decades. A muscle product with 0 published results on any of those, across more than 30 years in which every one of them was available, has not been tested against a hard standard or an easy one.
What is cited and why. The 2022 transport review supplies the PEPT1 substrate range that constrains the oral route. The 2019 docking screen covers 108,800 peptide-DNA complexes at a threshold near -32 and screens defined sequences only. The 2021 independent systematic review pooled 24 randomized trials over 2,245 participants on cognitive endpoints and graded certainty low to very low. 3 real papers, 0 of them about muscle.
What is actually measured, and what is not. Measured: nothing, in 0 published studies. Not measured, and this is the striking list: fractional synthetic rate by stable-isotope tracer, which is the gold-standard measurement of the exact quantity this class claims to change; grip strength; lean mass by DEXA; a 1-repetition maximum. Also not measured: composition, oral bioavailability, and whether the contents differ in any way from a hydrolyzed animal-protein supplement.
Not proven is not the same as disproven. Everything above says the evidence is weak. None of it says the compound does nothing. There is no adequately powered trial that ran and came back null, because outside Russia there is essentially no trial at all — this class is unfunded, not failed. A reader who leaves thinking “disproven” has learned something false, and so has one who leaves thinking “proven”.
Gotratix pharmacokinetics — how much of it actually gets in
'Not characterized' is the honest field value. A mixture has one clearance curve per component and 0 measurements exist for this preparation in any species.
What can be reasoned, and the awkward comparison. A short peptide reaching plasma meets serum aminopeptidases and clears in minutes. That is survivable for a transcriptional claim. What is less survivable is the comparison to what already goes into muscle: dietary protein is broken down by gastric and pancreatic proteases into the same amino-acid pool this capsule would enter, several times a day, and the anabolic response to a meal is one of the most-measured phenomena in this field. A capsule of unspecified peptide is entering a compartment that is already flooded, several times a day, by something with an enormous evidence base.
The oral barrier, and why it bites twice here. Gastric acid, pancreatic proteases, then the brush border of the small intestine, where PEPT1 carries di- and tripeptides — 2 and 3 residues — and not complexes, then hepatic first-pass extraction. 0 oral bioavailability figures have been published for any product in this family; an injection is 100% bioavailable by definition. The second bite is conceptual: PEPT1 is the transporter by which ordinary dietary di- and tripeptides are absorbed, so if a muscle extract's peptides do cross it, they cross as nutrition, arriving in the same pool as everything else in the meal.
Now do the arithmetic the blank was hiding. Compare the oral products in this class against the injectable ones and the oral form carries roughly 29x more material per day, and on the order of 571x more across a full course. Take an injection as fully bioavailable — 100% by definition, no gut wall, no hepatic first-pass — and the implication is direct: for the oral route to deliver comparable systemic exposure, on the order of 0.2% of what is swallowed would have to arrive in the circulation intact. Whether a peptide mixture can manage that has never been measured — not for this product and not for any product in this family. Stating the bound is honest. Claiming the fraction would not be.
What would have to be true for Gotratix to work
The chain. (1) The capsule would have to contain active peptides — 0 published assays. (2) A fraction would have to cross the gut wall as something other than ordinary nutrition — the named route, PEPT1, is the same one dietary di- and tripeptides use. (3) It would have to reach myofibers at a concentration that matters against the grams of amino acid arriving with every meal — never measured. (4) It would have to change transcription there — never observed. (5) Muscle protein synthesis or a functional outcome would have to move — and the methods to check that have existed for decades.
The one measurement that matters most is not a blood test. Grip strength, measured with the same dynamometer and the same protocol before and after 8-12 weeks, is repeatable, validated as a proxy for whole-body strength, needs no laboratory and costs nothing per repeat. The class doctrine on this site is to test the organ rather than the peptide. For this organ the test is a dynamometer, read at baseline and again at 8-12 weeks, and anyone running a course without one has decided in advance not to find out.
- Prediction 1 — grip strength. should improve, and it is the single most informative measurement on this page, 8-12 weeks, with the same dynamometer and the same protocol. This is not a blood test and that is the point. Grip strength is a validated proxy for whole-body strength, it is repeatable, it needs no laboratory, and it is the endpoint a muscle claim actually lives or dies on. Anyone who runs a course without measuring it has chosen not to find out.
- Prediction 2 — IGF-1 (Insulin-like Growth Factor 1). should NOT move; the band is age-dependent, roughly 115-355 ng/mL at 20-30 and lower each decade, baseline, then 6-8 weeks. A negative prediction, and it is the adulteration check for this category. The stated mechanism is local and transcriptional, so a systemic growth signal has no business rising. If it does, the explanation is more likely to be something in the capsule than something in the theory — and the age-adjusted range on your own report is the one to read against.
- Prediction 3 — Vitamin D (25-Hydroxy). should be in the 30-100 ng/mL sufficient band before anything else is tried, 8-12 weeks after a dose change. Deficiency is under 20 ng/mL, it is common, it is cheap to correct, and it is associated with muscle weakness. Correcting it first is what makes any later strength measurement mean something rather than nothing.
- Prediction 4 — Comprehensive Metabolic Panel (CMP). read the albumin and the liver enzymes, not just the glucose, every 3-6 months on any oral compound. Albumin is a crude but real index of protein status, and the same panel carries the liver enzymes that any oral product should be watched against. It is on the list as the baseline panel rather than as a muscle measurement, and saying so is more useful than pretending a CMP reports on muscle.
Run these before and after, not after alone. A single post-course number tells you what your body is doing, not what Gotratix did to it — and that difference is the entire point of testing.
Gotratix versus the alternatives
Gotratix versus the 2 interventions that actually build muscle, and this is the least close comparison on the whole site. Progressive resistance training and adequate protein intake have a randomized-trial literature spanning more than 40 years, thousands of participants, every age group including the very old, and endpoints that include strength, lean mass and physical function. Creatine monohydrate sits behind them as probably the most-studied ergogenic supplement in existence, with hundreds of trials over more than 30 years and a known effect size. Against that, a capsule with 0 published results is not an alternative; it is a distraction with a price.
And against its own class. If the tissue-specificity claim were true, a muscle extract would be the least interesting member of the family, because muscle is the one tissue you can already load directly with training and feed directly with protein. The organs where a targeted intervention would be genuinely valuable are the ones you cannot exercise: the kidney, whose filtration is read as cystatin C against 0.62-1.15 mg/L, and the retina, which has no blood test at all. This product is aimed at the tissue that needs the help least and responds to free interventions the most.
What you are actually buying when you buy Gotratix
A muscle extract cannot be identity-tested. A certificate covers sterility, endotoxin, total protein and named contaminants, and cannot establish contents, because the product is defined by its process and has no molecular formula, isoelectric point or mass to confirm against, unlike a synthetic of 3 or 4 residues where 1 mass-spectrometry run settles it.
The specific thing to notice on the label. A hydrolyzed animal-muscle preparation and a hydrolyzed animal-protein supplement are not obviously different products — both are protein hydrolysates made by protease digestion — and one of them is sold by the tub for a small fraction of the price. Ask what distinguishes them, and note what a certificate would have to show to answer: a compositional profile, which 0 vendors in this market publish for any organ extract. Until one does, the difference between this capsule and food is an assertion.
A muscle extract cannot be identity-tested and a capsule certificate does not describe what leaves the gut. The specific thing worth noticing is the scale mismatch: skeletal muscle is the largest tissue in the body by mass, so a capsule's contents are being asked to act on the biggest compartment there is, entering it through the same PEPT1 route the 2022 transport review reserves for peptides of 2 and 3 residues. The class's tissue-specificity argument is at its weakest exactly here.
Where to get Gotratix
Buy Gotratix at BioLongevity Supplements →The evidence for Gotratix
Graded by what exists behind each claim.
Human clinical evidence
- No randomized human trials — a research compound with no commercial route to funding one, so the correlative and theoretical tiers are the evidence base rather than a consolation prize.
📊 Correlative data
- The Khavinson group reported improvements in organ-specific markers across a long series of studies from the 1980s onward. These are overwhelmingly small, single-arm, and published in Russian-language journals; independent replication outside that school is close to absent.
🧪 How the mechanism reads
- The proposal is tissue specificity: a short peptide fraction taken from one organ acts preferentially on that same organ, binding regulatory DNA sequences and shifting protein synthesis toward a younger pattern. It is a coherent mechanism and it is why these are dosed as short courses rather than continuously.
- Oral delivery is the open question, not the mechanism. Peptides are poorly absorbed intact from the gut, which is why the oral capsules run 10-20x the injectable milligram dose. Whether enough survives to reach the target tissue has not been shown in a way anyone outside the manufacturer can check.
What that tier rests on here. The tier above is class inference. Nothing is indexed under the trade name Gotratix and 0 strength, lean-mass or muscle protein synthesis results have been published — despite the fact that the class's own claim is about protein synthesis and the gold-standard method for measuring it has existed for decades.
Why an empty tier is not a verdict →
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
Cell, rodent, human — and where it stops
Here is the finding that matters most on this page, and it is an absence. Ryzhak 2015 is the group's own comparison of calf-tissue polypeptide extracts in organotypic culture, and it covers seven tissues: cortex, pineal, liver, prostate, thymus, heart and cartilage. Skeletal muscle is not among them. So this product does not have even the cell-culture result that the better-served members of its own class have. The tissue was left out of the survey that defines the category.
The class-level papers do not fill the gap. Khavinson 2012 and Khavinson 2001 assert tissue specificity as a general principle; Khavinson 2021 reviews gene-expression effects across the family; Khavinson 2022 models carriage on peptide and amino acid transporters computationally. None of them measured anything in a myocyte, a muscle fiber or a moving animal.
And muscle is the tissue where that absence is least excusable. The quantity this class claims to restore — tissue protein synthesis — has a gold-standard measurement in skeletal muscle: fractional synthetic rate, by stable-isotope tracer infusion with a biopsy. It has been in routine use in exercise physiology for over thirty years. Grip strength, DEXA lean mass and a one-repetition maximum are cheaper still. Every one of those has been available for the entire commercial life of this product and none has been published for it.
Where it stops. A PubTator3 search on 6 September 2026 returned no indexed record under this trade name in any language, and no strength, lean-mass or protein-synthesis endpoint for any muscle peptide preparation in this family.
What nobody has tested yet
A dynamometer and eight weeks. Grip strength is validated as a proxy for whole-body strength, predicts mortality in older adults, costs nothing per repeat measurement and requires no laboratory. It is the single most informative number a person taking this could collect, and no published study has collected it.
The comparison that would settle the value question. An unspecified peptide capsule enters the same amino-acid pool that dietary protein floods several times a day. A trial with three arms — the capsule, an isonitrogenous protein supplement, and nothing — would answer within twelve weeks whether the tissue of origin adds anything to the nitrogen. It has never been attempted.
Extrapolation, labeled as such. If the tissue-specificity doctrine is right, a muscle extract should be the least useful member of the family, not the most: muscle is the one target organ you can already load directly with resistance training and feed directly with protein, both with enormous randomized evidence behind them. A product whose own theory predicts it should be redundant is an unusual thing to sell, and nobody in this market states it.
Sources read for this page
- Ryzhak AP, Chalisova NI, Lin'kova NS, Khalimov RI, Ryzhak GA, Zhekalov AN. [Polypeptides influence on tissue cell cultures regeneration of various age rats]. Advances in Gerontology 2015;28(1):97-103 [Russian] · PMID 26390619
- Khavinson VKh. Peptides tissue-specifically stimulate cell differentiation during their aging. Bulletin of Experimental Biology and Medicine 2012 · PMID 22808515
- Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. International Journal of Molecular Sciences 2022;23(14):7733 · PMID 35887081
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules 2021;26(22):7053 · PMID 34834147
- Khavinson VK. Tissue-specific effects of peptides. Bulletin of Experimental Biology and Medicine 2001;132(2):807-808 · PMID 11713572
Gotratix — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a skeptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a skeptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Gotratix — safety specifics for this compound
Specific to Gotratix: 0 adverse-event data exist for any skeletal-muscle preparation in this family, and the compound-level risk is unstudied rather than known to be low. The named risk is misattribution with a delay attached, because unexplained muscle weakness has a differential that ordinary tests cover and some of it matters. Hypothyroidism, vitamin D deficiency below the 20 ng/mL threshold, B12 deficiency against a 232-1,245 pg/mL band, statin-associated muscle symptoms and the inflammatory myopathies all present as weakness, and the last group raises creatine kinase and needs specialist care rather than a supplement. New weakness that is progressive, asymmetric, or accompanied by dark urine after exertion is a reason to be seen rather than to start a course. The second point is smaller and worth saying: this is the one target in the cohort where the alternative is free, so the opportunity cost of 3 months on a capsule is measured in training sessions.
Gotratix — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Gotratix moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
These are short peptide fragments given in microgram amounts and there is no mechanism predicting a specific marker shift. Listing markers here would be padding.
What to do: Test the organ system the bioregulator is aimed at, not a generic panel — that is the only measurement that would tell you anything.
The evidence base here is almost entirely one research group's, largely in Russian, and rarely replicated independently. That is the single most important thing to know before running a course, and it is more useful than any interaction list.
Gotratix — what interferes with this one specifically
The interference specific to this page is that the endpoint is trivially confounded by the thing everyone buying it is also doing. Anyone who starts a muscle product and a training block in the same month has 2 variables, and resistance training has an effect size on strength that dwarfs anything an unstudied extract could plausibly add. The same goes for a protein intake that changes at the same time, and for creatine, which raises intracellular water and body mass within 2-4 weeks and will make a scale or a DEXA read differently for reasons that have nothing to do with the capsule. Creatine also raises serum creatinine and therefore lowers the eGFR printed on a comprehensive metabolic panel, which is worth knowing before anyone panics. The mitigation is the one that makes any n=1 experiment readable: hold training and nutrition constant across the before-and-after window, change 1 thing, and measure grip strength with the same device. Second: 0 interaction studies exist for any compound in this class, so nothing above is an observed interaction with this product.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Gotratix in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Gotratix
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Gotratix — frequently asked questions
Is Gotratix a peptide or an extract?
An extract — a peptide complex from skeletal muscle, not a single defined molecule. That is why a certificate of analysis cannot confirm its identity the way it can for a synthetic peptide.
Is there a human trial of Gotratix?
Nothing is indexed under the trade name Gotratix. No strength, lean-mass or muscle protein synthesis endpoint has been published for a skeletal-muscle peptide preparation in this family.
What should I measure if I run Gotratix?
Before and after, not after alone. The falsifiability section on this page names the specific markers, the direction each should move and the timescale — and says what a null result would rule out.
References & further reading
- Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M — Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers · International Journal of Molecular Sciences 2022;23(14):7733 · PMID 35887081
- Kolchina N, Khavinson V, Linkova N, Yakimov A, Baitin D, Afanasyeva A, Petukhov M — Systematic search for structural motifs of peptide binding to double-stranded DNA · Nucleic Acids Research 2019;47(20):10553–10563 · PMID 31598715
- Alsulaimani RA, Quinn TJ (independent — not the Khavinson group) — The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis · Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709
What Gotratix is used for
Gotratix appears under 2 goals in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.